이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Vertex Pharmaceuticals 대차 대조표 상태
재무 상태 기준 확인 6/6
Vertex Pharmaceuticals 의 총 주주 지분은 $18.5B 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $23.9B 및 $5.4B 입니다. Vertex Pharmaceuticals 의 EBIT는 $4.4B 이며 이자보상배율은 -7 입니다. $10.2B 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보
0%
부채 비율
US$0
부채
이자 보상 비율 | -7x |
현금 | US$10.17b |
주식 | US$18.55b |
총 부채 | US$5.37b |
총 자산 | US$23.92b |
최근 재무 상태 업데이트
업데이트 없음
Recent updates
If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jun 20Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales
Jun 17Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
Jun 04Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet
May 09Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 08Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
Apr 11Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely
Apr 05Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?
Mar 15Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings
Feb 22Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Jan 15Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Dec 25An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued
Nov 13With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Oct 02Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jul 31We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease
Jul 03An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued
Apr 30With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Apr 03An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued
Jan 23If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jan 02재무 상태 분석
단기부채: VRTX 의 단기 자산 ( $13.3B )이 단기 부채( $3.8B ).
장기 부채: VRTX 의 단기 자산( $13.3B )이 장기 부채( $1.6B ).
부채 대 자본 내역 및 분석
부채 수준: VRTX 부채가 없습니다.
부채 감소: VRTX 5년 전에 부채가 없었습니다.
부채 범위: VRTX 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.
이자 보장: VRTX 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.